Your browser doesn't support javascript.
loading
Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
Luo, Hong-Yu; Gao, Li-Chen; Long, Hui-Zhi; Zhou, Zi-Wei; Xu, Shuo-Guo; Li, Feng-Jiao; Li, Hong-Li; Cheng, Yan; Li, Cai-Xia; Peng, Xing-Yu; Li, Liang; Chen, Ran; Deng, Ping.
Afiliação
  • Luo HY; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Gao LC; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Long HZ; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China. 89206346@qq.com.
  • Zhou ZW; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China. 89206346@qq.com.
  • Xu SG; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Li FJ; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Li HL; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Cheng Y; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Li CX; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Peng XY; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Li L; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Chen R; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Deng P; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Eur J Clin Pharmacol ; 79(5): 663-670, 2023 May.
Article em En | MEDLINE | ID: mdl-36976322
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neprilisina / Insuficiência Cardíaca / Hipotensão Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Clin Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neprilisina / Insuficiência Cardíaca / Hipotensão Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Clin Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China